ArticleCell and tissue banking2026
Dimethyl fumarate as an immunomodulatory enhancer of adipose-derived mesenchymal stem cells: therapeutic implications.
Article in Cell and tissue banking, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adipose-drive stem cells (ASCs) are similar to Mesenchymal stem cells (MSCs), which are considered as multipotent progenitors that have capable of immunomodulation, self-renewal and differentiation into multiple cell lineages that can be used in cancer therapy or immune diseases. Dimethyl fumarate (DMF) is one of the important drugs with modulating function for treatment of various immune disease. The primary aim of this study was to investigate how dimethyl fumarate influences the immunomodulatory profile and functional properties of adipose‑derived mesenchymal stem cells under inflammatory conditions. Adipose-stimulating stem cells (ASCs) were isolated from the abdominal adipose tissue of ten patients via liposuction, and DMF was added after inducing inflammatory conditions with inflammatory cytokines such as IFN-γ and TNF-α. Cell culture and RT-PCR were performed to measure the expression of immunomodulatory factors such as Galectin-1/3, HGF, HO-1, CXCL-8, and IL-6. Flow cytometry for mesenchymal stem cell nature and confirmation was done. Fat and bone staining was performed to test the functional differentiation of these cells. ASCs treated with DMF at 0.01-100 μM concentration at 2 days showed the enhancement of CXCL-8 and IL-6 gene expression notably, whereas, HGF, and Galectin-1 reduced. Moreover, Galectin-3 and HO-1 depicted no significant difference compared to the control group. Further, Alizarin Red and Oil Red staining verified the change of MSCs toward adipose and osteogenic differentiation. ASCs are positive for markers including CD73+, CD90+, and CD105+ antigens by abs staining conjugated to fluorescence dye. Our study confirmed that ASCs combined with DMF have increasingly important roles through immune-modulatory properties by secreting mediators, which can suppress, improve, alter, or change the microenvironment of disease. Despite ongoing progress, the underlying stimulatory and regulatory mechanisms remain incompletely understood. The gap between pre‑clinical findings and clinical applications highlights the need for further investigation. Extensive research is still required to elucidate how therapeutic interventions achieve efficacy, ensure safety, and identify optimal strategies for targeting different organs in combination with other pharmacological agents.
Indexed as
Identifiers
41665712What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.